Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer
Open Access
- 17 September 2013
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 109 (7), 1735-1743
- https://doi.org/10.1038/bjc.2013.523
Abstract
Background: Mean survival in cancer trials can be estimated with statistical techniques to extrapolate study survival curves. This methodology was applied to data from the VELOUR trial, where use of the novel biologic aflibercept (ziv-aflibercept in the United States) in combination with fluorouracil+leucovorin+irinotecan (FOLFIRI), had significantly increased median overall survival (OS) by 1.44 months, vs placebo plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) resistant to, or that had progressed following, an oxaliplatin-containing regimen. Methods: Parametric survival analyses were used to identify distributions with the best fit to the empirical VELOUR data. Mean OS for the two treatment groups (and pre-defined subgroups) was calculated from the fitted curves over a 15-year survival period. Results: Overall, the log-logistic distribution was the best-fitting for both treatment arms and, with it, the estimated difference in mean OS over 15 years between aflibercept+FOLFIRI and placebo+FOLFIRI was 4.7 months. In addition, the survival advantage with aflibercept was at least 3 months for the ITT population, whichever distribution was used to extrapolate survival. Conclusion: Extrapolation of survival curves suggests the mean OS difference for aflibercept in the VELOUR trial is at least 3 months in the ITT population and selected subgroups.This publication has 22 references indexed in Scilit:
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based RegimenJournal of Clinical Oncology, 2012
- Modelling survival in hepatocellular carcinomaCurrent Medical Research and Opinion, 2012
- The Ends Justify the Mean: Outcome Measures for Estimating the Value of New Cancer TherapiesHealth Outcomes Research in Medicine, 2012
- Cautions Regarding the Fitting and Interpretation of Survival CurvesPharmacoEconomics, 2011
- Systemic Therapy for Metastatic Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology PracticeJournal of Oncology Practice, 2010
- Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741Journal of Clinical Oncology, 2008
- Long-Term Survival After Colon Cancer Surgery: A Variation Associated with Choice of AnesthesiaAnesthesia & Analgesia, 2008
- The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal CancerThe Oncologist, 2007
- Ascertaining Prognosis for Breast Cancer in Node-Negative Patients with Innovative Survival AnalysisThe Breast Journal, 2006
- The Lognormal Distribution as a Model for Survival Time in Cancer, With an Emphasis on Prognostic FactorsStatistica Neerlandica, 2001